Profound Medical Corp. (PROF)
Profound Medical Statistics
Share Statistics
Profound Medical has 30.04M shares outstanding. The number of shares has increased by 22.97% in one year.
| Shares Outstanding | 30.04M |
| Shares Change (YoY) | 22.97% |
| Shares Change (QoQ) | 0.04% |
| Owned by Institutions (%) | 55.89% |
| Shares Floating | 26.63M |
| Failed to Deliver (FTD) Shares | 9.36K |
| FTD / Avg. Volume | 12.44% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -6.69 and the forward PE ratio is -3.64. Profound Medical's PEG ratio is 0.39.
| PE Ratio | -6.69 |
| Forward PE | -3.64 |
| PS Ratio | 17.41 |
| Forward PS | 1 |
| PB Ratio | 3.08 |
| P/FCF Ratio | -7.93 |
| PEG Ratio | 0.39 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Profound Medical.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.52, with a Debt / Equity ratio of 0.08.
| Current Ratio | 10.52 |
| Quick Ratio | 9.64 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | -0.15 |
| Debt / FCF | -0.22 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $75.21K |
| Profits Per Employee | $-195.89K |
| Employee Count | 142 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0.63 |
Taxes
| Income Tax | -2K |
| Effective Tax Rate | -0.01% |
Stock Price Statistics
The stock price has increased by -35.35% in the last 52 weeks. The beta is 0.62, so Profound Medical's price volatility has been higher than the market average.
| Beta | 0.62 |
| 52-Week Price Change | -35.35% |
| 50-Day Moving Average | 6.08 |
| 200-Day Moving Average | 7.55 |
| Relative Strength Index (RSI) | 39.05 |
| Average Volume (20 Days) | 75.19K |
Income Statement
In the last 12 months, Profound Medical had revenue of 10.68M and earned -27.82M in profits. Earnings per share was -1.12.
| Revenue | 10.68M |
| Gross Profit | 7.04M |
| Operating Income | -33.06M |
| Net Income | -27.82M |
| EBITDA | -33.06M |
| EBIT | -33.06M |
| Earnings Per Share (EPS) | -1.12 |
Balance Sheet
The company has 54.91M in cash and 5.12M in debt, giving a net cash position of 49.79M.
| Cash & Cash Equivalents | 54.91M |
| Total Debt | 5.12M |
| Net Cash | 49.79M |
| Retained Earnings | 0 |
| Total Assets | 70.23M |
| Working Capital | 62.5M |
Cash Flow
In the last 12 months, operating cash flow was -23.45M and capital expenditures 0, giving a free cash flow of -23.45M.
| Operating Cash Flow | -23.45M |
| Capital Expenditures | 0 |
| Free Cash Flow | -23.45M |
| FCF Per Share | -0.95 |
Margins
Gross margin is 65.89%, with operating and profit margins of -309.57% and -260.45%.
| Gross Margin | 65.89% |
| Operating Margin | -309.57% |
| Pretax Margin | 260.47% |
| Profit Margin | -260.45% |
| EBITDA Margin | -309.57% |
| EBIT Margin | -309.57% |
| FCF Margin | -219.6% |
Dividends & Yields
PROF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for PROF is $11.5, which is 139.1% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.5 |
| Price Target Difference | 139.1% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Oct 16, 2019. It was a backward split with a ratio of 1:10.
| Last Split Date | Oct 16, 2019 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | 3.3 |
| Piotroski F-Score | 4 |